Indication assessment · §3

Hypertension in the context of adiposity — trial records

Trial records in the Institute's register bearing on hypertension in the context of adiposity.

Document identifier: CEI-IN-17/3
Series: Indication assessment
Version: 1.0
Published: 13 Jul 2023
Last reviewed: 13 Jul 2023
Next review: 13 Jul 2025
Identifier: 10.71829/cei.ind.17
Certainty: Not rated
Cycle: 2023 Q3
ICD-11: BA00
Category: Cardiovascular

§3Trials in this indication

0 trial records in the Institute's register bear on this indication, of which 0 are published trials.

No trial record bears on this indication.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Compound Evidence Institute · CEI-IN-17/3 · https://compoundevidence.com/indications/hypertension/trials/ · retrieved 30 July 2026